SEC Form 4 · accession 0001654954-17-005408
Cellular Biomedicine Group, Inc. · CBMG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tony Liu
Officer — CEO, CFO · Director
Period of report
Jun 6, 2017
Accepted (ET)
Jun 7, 2017 · 11:58 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001378624
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 6, 2017 | P | 800 | $6.81 | A | 119,825 | D | |
| Common Stock | Jun 6, 2017 | P | 100 | $6.78 | A | 119,925 | D | |
| Common Stock | Jun 6, 2017 | P | 2,000 | $6.83 | A | 121,925 | D | |
| Common Stock | Jun 6, 2017 | P | 2,100 | $6.84 | A | 124,125 | D | |
| Common Stock | Jun 6, 2017 | P | 100 | $6.85 | A | 124,125 | D | |
| Common Stock | Jun 6, 2017 | P | 800 | $6.80 | A | 124,925 | D | |
| Common Stock | Jun 6, 2017 | P | 1,200 | $6.84 | A | 124,925 | D | |
| Common Stock | Jun 6, 2017 | P | 2,900 | $6.85 | A | 129,025 | D |
Table II — derivative securities
No Table II lines on this filing.